The stock of TransCode Therapeutics Inc (RNAZ) has seen a -52.03% decrease in the past week, with a -65.24% drop in the past month, and a -69.66% decrease in the past quarter. The volatility ratio for the week is 10.44%, and the volatility levels for the past 30 days are at 13.50% for RNAZ. The simple moving average for the past 20 days is -58.59% for RNAZ’s stock, with a -81.63% simple moving average for the past 200 days.
Is It Worth Investing in TransCode Therapeutics Inc (NASDAQ: RNAZ) Right Now?
The 36-month beta value for RNAZ is also noteworthy at 0.57. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RNAZ is 0.70M, and at present, short sellers hold a 2.62% of that float. The average trading volume of RNAZ on December 18, 2024 was 47.66K shares.
RNAZ) stock’s latest price update
The stock price of TransCode Therapeutics Inc (NASDAQ: RNAZ) has dropped by -40.06 compared to previous close of 6.32. Despite this, the company has seen a fall of -52.03% in its stock price over the last five trading days. prnewswire.com reported 2024-12-18 that Approval given after Safety Review Committee (SRC) review of safety data from the three patients comprising Cohort 2 No significant safety or dose limiting toxicities reported in Cohort 2 New patients currently being evaluated for eligibility in Cohort 3 PK and PD data from Cohort 1 patients consistent with preclinical and Phase 0 trial results BOSTON, Dec. 18, 2024 /PRNewswire/ — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC) monitoring its Phase 1 clinical trial has unanimously approved opening of the third cohort of patients based on its favorable review of Cohort 2 safety data. The therapeutic candidate being evaluated, TTX-MC138, is TransCode’s lead candidate designed to inhibit microRNA-10b, or miR-10b, a microRNA critical to the emergence and progression of many metastatic cancers.
RNAZ Trading at -73.32% from the 50-Day Moving Average
After a stumble in the market that brought RNAZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.57% of loss for the given period.
Volatility was left at 13.50%, however, over the last 30 days, the volatility rate increased by 10.44%, as shares sank -68.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -78.89% lower at present.
During the last 5 trading sessions, RNAZ fell by -57.41%, which changed the moving average for the period of 200-days by -85.18% in comparison to the 20-day moving average, which settled at $9.12. In addition, TransCode Therapeutics Inc saw -98.26% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RNAZ
Current profitability levels for the company are sitting at:
- -19.47 for the present operating margin
- 0.44 for the gross margin
The net margin for TransCode Therapeutics Inc stands at -19.82. The total capital return value is set at -8.88. Equity return is now at value -490.03, with -210.77 for asset returns.
Currently, EBITDA for the company is -17.97 million with net debt to EBITDA at 0.12. When we switch over and look at the enterprise to sales, we see a ratio of 1.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.58.
Conclusion
In summary, TransCode Therapeutics Inc (RNAZ) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
